Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Surgery Partners (SGRY) EBIAT (2016 - 2025)

Surgery Partners' EBIAT history spans 12 years, with the latest figure at $29.0 million for Q4 2025.

  • For Q4 2025, EBIAT rose 112.76% year-over-year to $29.0 million; the TTM value through Dec 2025 reached $98.9 million, up 158.83%, while the annual FY2025 figure was $98.9 million, 158.83% up from the prior year.
  • EBIAT for Q4 2025 was $29.0 million at Surgery Partners, up from $25.3 million in the prior quarter.
  • Across five years, EBIAT topped out at $146.2 million in Q4 2023 and bottomed at -$227.2 million in Q4 2024.
  • The 5-year median for EBIAT is $14.8 million (2021), against an average of $12.5 million.
  • The largest YoY upside for EBIAT was 979.59% in 2024 against a maximum downside of 1133.33% in 2024.
  • A 5-year view of EBIAT shows it stood at $42.9 million in 2021, then surged by 175.52% to $118.2 million in 2022, then grew by 23.69% to $146.2 million in 2023, then crashed by 255.4% to -$227.2 million in 2024, then soared by 112.76% to $29.0 million in 2025.
  • Per Business Quant, the three most recent readings for SGRY's EBIAT are $29.0 million (Q4 2025), $25.3 million (Q3 2025), and $44.9 million (Q2 2025).